NB S101 contains strontium malonate as its active ingredient. The primary endpoint of the study is the change in patients' bone resorption. Osteologix plans to enroll postmenopausal women with low bone mineral density and treat them for 12 weeks in the clinical trial.
“There is a significant need for improved osteoporosis treatments. We believe NB S101 may have the ability to both increase bone formation and decrease bone resorption, while also reducing the side effects most common in osteoporosis drugs available today,” stated Charles Casamento, CEO and president.
In addition to the primary endpoint of quantifying bone resorption, Osteologix plans to evaluate the effect of NB S101 on bone formation by measuring markers specific for this process. Other secondary endpoints being evaluated include the effects of NB S101 on bone mineral density, strontium levels and markers of cartilage degradation.